Free Trial

Hall Capital Management Co. Inc. Invests $2.07 Million in Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. logo with Medical background

Hall Capital Management Co. Inc. purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 20,826 shares of the company's stock, valued at approximately $2,072,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Midwest Capital Advisors LLC acquired a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $26,000. Financial Life Planners acquired a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC acquired a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $28,000. Halbert Hargrove Global Advisors LLC acquired a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $28,000. Finally, Promus Capital LLC acquired a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $30,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, SVP Dalton E. Smart III sold 4,262 shares of the business's stock in a transaction dated Friday, April 25th. The stock was sold at an average price of $82.76, for a total transaction of $352,723.12. Following the completion of the transaction, the senior vice president now owns 7,778 shares of the company's stock, valued at approximately $643,707.28. The trade was a 35.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.09% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms have recently commented on MRK. Cantor Fitzgerald cut shares of Merck & Co., Inc. from an "overweight" rating to a "cautious" rating in a research report on Tuesday, May 20th. TD Cowen cut shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating and reduced their target price for the stock from $121.00 to $100.00 in a research report on Monday, February 10th. BMO Capital Markets reduced their target price on shares of Merck & Co., Inc. from $105.00 to $96.00 and set a "market perform" rating on the stock in a research report on Wednesday, February 5th. Bank of America reduced their target price on shares of Merck & Co., Inc. from $118.00 to $112.00 and set a "buy" rating on the stock in a research report on Wednesday, February 5th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating and reduced their target price for the stock from $128.00 to $105.00 in a research report on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seven have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $109.19.

Check Out Our Latest Research Report on Merck & Co., Inc.

Merck & Co., Inc. Stock Performance

MRK stock traded down $1.42 during midday trading on Wednesday, reaching $76.17. 12,271,678 shares of the company were exchanged, compared to its average volume of 12,567,482. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. The business has a 50-day moving average price of $81.09 and a two-hundred day moving average price of $91.05. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $134.63. The firm has a market capitalization of $191.27 billion, a price-to-earnings ratio of 11.32, a price-to-earnings-growth ratio of 0.77 and a beta of 0.43.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $2.22 earnings per share for the quarter, topping analysts' consensus estimates of $2.16 by $0.06. Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The company had revenue of $15.53 billion during the quarter, compared to the consensus estimate of $15.59 billion. During the same quarter last year, the firm earned $2.07 earnings per share. The company's revenue was down 1.6% on a year-over-year basis. Equities research analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. announced that its Board of Directors has approved a stock buyback plan on Tuesday, January 28th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 4.1% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 8th. Investors of record on Monday, June 16th will be paid a $0.81 dividend. This represents a $3.24 dividend on an annualized basis and a yield of 4.25%. The ex-dividend date is Monday, June 16th. Merck & Co., Inc.'s dividend payout ratio (DPR) is presently 47.16%.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Read More

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Should You Invest $1,000 in Merck & Co., Inc. Right Now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines